Core Points - The China Traditional Chinese Medicine Association (CTCMA) aims to serve the TCM industry and has over 900 member enterprises and 67 branches, gathering more than 10,000 experts in the field [1][3] - The second term of the Microcirculation Medication Professional Committee was inaugurated on May 10, 2025, in Zhengzhou, marking a new beginning for the committee [1][3] - The new committee plans to focus on collaborative innovation, deepening TCM research, academic dissemination, and policy research to enhance the quality of TCM development [15][18] Summary of Key Sections Inauguration and Leadership - The second term of the Microcirculation Medication Professional Committee was successfully held with over 160 attendees, including experts and representatives from various institutions [1][3] - Wang Xiaolong from Shanghai University of Traditional Chinese Medicine was elected as the new chairman, with 215 new committee members elected [10][8] Achievements of the First Committee - The first committee achieved significant results in organizational development, academic exchange, and public health awareness, including hosting four "Craftsman National Medicine Innovation Development Conferences" and reaching over 100,000 online viewers [5][12] - The committee also provided a platform for over 1,000 specialists through evidence-based TCM research lectures [5] Future Work Plan - The second committee's five-year work plan includes promoting collaborative innovation, enhancing TCM research and application, academic dissemination, and policy research [15][18] - The committee aims to accumulate scientific evidence for the application of TCM products in microcirculation and improve clinical efficacy and patient quality of life [15][18] Emphasis on Party Building - The association emphasized the importance of party building in guiding the committee's work and ensuring compliance with national laws and regulations [12][19] - The committee plans to strengthen its activities and improve the quality of its operations in alignment with the association's goals [17][19]

Financial Performance - The company's revenue for the fiscal year 2024 was RMB 16.51 billion, a decrease of 8.9% compared to RMB 18.12 billion in 2023[16]. - Net profit for the fiscal year 2024 was RMB 0.21 billion, down 98.5% from RMB 12.85 billion in 2023[16]. - The gross profit margin for 2024 was 47.59%, a decline from 51.18% in 2023[8]. - The operating profit margin dropped to 2.03% in 2024 from 7.88% in 2023[8]. - The total assets as of December 31, 2024, were RMB 35.06 billion, down from RMB 37.07 billion in 2023[8]. - The group's revenue for the year ended December 31, 2024, was approximately RMB 16.51 billion, a decrease of 8.9% compared to RMB 18.12 billion in the previous year, primarily due to policy impacts on the granule industry and intensified market competition[23]. - The gross profit was approximately RMB 7.86 billion, down 15.3% from RMB 9.27 billion in the same period last year, with a gross margin of 47.6%, a decline of 3.6 percentage points year-on-year[24]. - The group's profit for the year ended December 31, 2024, was approximately RMB 20,771,000, a decrease of 98.5% compared to RMB 1,396,070,000 in 2023, with a net profit margin of 0.1%[77]. - The adjusted profit for the year ended December 31, 2024, was approximately RMB 635,540,000, a decline of 54.5% from RMB 1,396,070,000 in 2023[79]. - Basic earnings per share for the 12 months ended December 31, 2024, were RMB 0.0107, a decrease of 95.8% from RMB 0.2552 in 2023[81]. Market and Business Strategy - The company maintained a stable market share despite the overall decline in profitability due to macroeconomic fluctuations and increased competition[16]. - The company aims to strengthen its core business areas, including traditional Chinese medicine granules and proprietary Chinese medicines, to explore new growth opportunities[17]. - The company is focusing on five major business segments: production and operation of traditional Chinese medicine materials, traditional Chinese medicine pieces, traditional Chinese medicine granules, proprietary Chinese medicines, and traditional Chinese medicine health products[25]. - The company is focusing on digital transformation and innovation in traditional Chinese medicine, with ongoing projects in new drug development and supply chain management improvements[17]. - The company aims to enhance its core competitiveness and overall strength through resource integration and reform transformation[19]. Research and Development - The group has established 2 national enterprise technology centers, 2 academician workstations, and 3 national medicine master studios, among other research facilities, as of December 31, 2024[36]. - The group achieved breakthroughs in traditional Chinese medicine resource research, with new varieties "Guo Qiao No. 1" and "Gui Tong Rou Mao No. 1" authorized by the Ministry of Agriculture and Rural Affairs of China[37]. - A total of 172 patents have been applied for, with 126 granted, including 68 invention patents, supporting technological innovation and product upgrades[38]. - The company has 2 new traditional Chinese medicine drugs and 17 classic formulas at different stages of research and development, holding 814 production licenses for pharmaceuticals[196]. - The R&D agreements aim to leverage expertise to develop new products and enhance the company's product portfolio, benefiting sustainable development[137]. Compliance and Governance - The company is committed to ESG governance, enhancing compliance and risk management, and promoting sustainable development initiatives[18]. - The company has established a comprehensive compliance review system, achieving zero major risk events during the reporting period[44]. - The company is committed to high standards of corporate governance, adhering to the Corporate Governance Code[156]. - The independent non-executive directors collectively possess extensive expertise in finance, accounting, and management, contributing to independent judgment on strategic and risk management matters[160]. - The board has adopted a diversity policy to enhance its effectiveness through various diversity aspects, including gender, age, and professional experience[176]. Operational Efficiency - The company has implemented a comprehensive quality control system to improve product quality and accessibility[18]. - The company has implemented a digital transformation strategy, with the "Longyin AI" model developed to enhance business efficiency and promote industrial intelligence[42]. - The group conducted 1,705 safety training sessions, significantly improving employee safety operation capabilities and reducing accident rates[43]. - The company has established a comprehensive training program for employees, covering various aspects such as marketing, production, human resources, and financial management[195]. - The company has implemented strict internal controls to ensure effective risk management and compliance with relevant regulations in relation to the agreements[127]. Financial Position and Investments - The group's current assets as of December 31, 2024, were approximately RMB 18,839,503,000, with a current ratio of 2.4 times, up from 2.1 times in 2023[81]. - The group utilized RMB 800 million in bank loans in the first half of 2024 and RMB 865 million in external financing in the second half for debt rollover and liquidity support[83]. - The group had unutilized bank loan facilities of approximately RMB 9,490,055,000 as of December 31, 2024, indicating a strong liquidity position[83]. - The total remuneration for employees during the reporting period was approximately RMB 2,412,832,000, compared to RMB 2,387,329,000 for the year ending December 31, 2023[88]. - The company aims to enhance its financial structure and diversify funding channels through the factoring service agreement[127]. Market Trends and Challenges - The revenue from traditional Chinese medicine granules decreased by 23.5% year-on-year to approximately RMB 6.97 billion, representing 42.2% of total revenue[23]. - The revenue and profit levels of the Chinese herbal formula granules segment have declined due to price reductions from centralized procurement and increased market competition[30]. - The revenue from traditional Chinese medicine pieces increased by 17.9% year-on-year to approximately RMB 3.31 billion, accounting for 20.1% of total revenue[23]. - The company reported that 316 national drug standards for Chinese herbal formula granules have been issued, which is significant for standardization and modernization of the industry[32]. - The company has expanded its "Traditional Chinese Medicine Health" business, with 34 new stores and over 160,000 patient visits in its integrated health services[35]. Shareholder and Management Information - The company has appointed Yang Jun as the executive director and chairman effective September 27, 2024[121]. - The company has appointed Li Hongjian as the executive director and president effective September 27, 2024[121]. - The board consists of 11 members, including 2 executive directors, 5 non-executive directors, and 4 independent non-executive directors, ensuring compliance with listing rules[160]. - The company has disclosed changes in director information as per the listing rules, with several appointments and resignations effective in 2024 and 2025[120]. - The independent non-executive directors have reviewed the ongoing related party transactions and confirmed compliance with the listing rules[139].

Core Viewpoint - "Yang Wujing Brand Pulmonary Pills" has been recognized as a trustworthy Chinese herbal medicine brand by CCTV, promoting the integration of traditional Chinese medicine with modern lung health needs [1][2]. Group 1: Brand Trust and Quality - The brand's trustworthiness is built on over 600 years of formula inheritance and more than a decade of strong brand strength, supported by authoritative scientific recognition [3]. - The product is based on the classic ancient formula "Pulmonary Decoction" from the 1331 Jin Yuan period, designed to enhance lung function and alleviate cough and asthma symptoms [4]. - The manufacturing process adheres to international standards such as ISO and GMP, ensuring high quality from raw material procurement to production [4]. Group 2: Scientific Validation and Clinical Application - Research conducted by the Chinese Academy of Traditional Chinese Medicine confirms the efficacy of Pulmonary Pills in treating various lung diseases, including COPD, lung cancer, and COVID-19 [6][7]. - The product has been included in treatment guidelines for COVID-19 recovery and chronic obstructive pulmonary disease, establishing its role in modern medical practices [8]. Group 3: Public Welfare and Community Engagement - The brand actively participates in public health initiatives, promoting lung health awareness through various outreach programs and collaborations with healthcare professionals [11]. - The brand's commitment to public health has positioned it as a trusted choice for families dealing with chronic lung conditions [10]. Group 4: Brand Development and Industry Impact - The growth of "Yang Wujing Brand Pulmonary Pills" reflects the broader trend of traditional Chinese medicine evolving to meet modern health demands, emphasizing quality and efficacy [14]. - The brand aims to enhance its influence in the industry by leveraging scientific research for quality upgrades and expanding its market presence [14].

中国中药公告，控股股东国药集团已于2025年4月8日从公开市场以每股平均价格约1.86港元直接增持本 公司5035万股股份。于本公告日期，国药集团直接及间接持有本公司16.85亿股股份，占本公司全部已 发行股份约33.46%。 ...

Summary of China Traditional Chinese Medicine (CTCM) Conference Call Company Overview - **Company**: China Traditional Chinese Medicine (CTCM) - **Industry**: Traditional Chinese Medicine Key Financial Highlights - **Special Dividend**: CTCM announced a special dividend of RMB 0.32 per share, totaling RMB 798 million, amounting to RMB 402 million in total [2][3] - **Revenue**: For 2024, CTCM reported revenue of approximately RMB 8.807 billion, with a gross margin of 18.69%, a decrease of 3.6 percentage points year-on-year [3] - **Net Profit**: Net profit was approximately RMB 20.07 million, a decline compared to the previous year [3] - **Assets and Liabilities**: As of the end of 2024, current assets were RMB 18.84 billion, down 5% from the end of 2023. Total assets were RMB 31.06 billion, with total liabilities reduced to RMB 10.03 billion [2][3] Business Segment Performance - **Chinese Medicine Production**: Growth observed in Chinese medicine production, Chinese medicine formula granules, and the health sector. The Chinese medicine hospital segment grew by 13% year-on-year, while the Chinese patent medicine segment showed significant growth [2][3] - **Chinese Patent Medicine Sales**: Sales in the Chinese patent medicine segment were approximately RMB 4.53 billion, accounting for 20.6% of total revenue, with a gross margin of 36% [2][5] - **Health Products**: The health product segment expanded through an integrated online and offline operational model, operating 30 stores with significant sales growth [2][5] Strategic Initiatives - **Reform and Compliance**: CTCM aims to deepen reforms and strengthen compliance, focusing on talent development, resource optimization, and production efficiency [2][6] - **Market Strategy**: The company plans to enhance brand differentiation, improve marketing efforts, and modernize governance structures to boost competitiveness and achieve sustainable development [2][6] - **2025 Strategic Focus**: CTCM will emphasize high-quality development in the health sector, integrating core industries and enhancing modernization, technology, globalization, and standardization [7] Market Challenges and Responses - **Volume-based Procurement**: The company faces challenges from volume-based procurement policies, with market share in some provinces around 18%, potentially reaching 30% when considering non-executing regions [2][10] - **Cost Control**: CTCM is implementing strategies to optimize existing industrial layouts, reduce costs, and improve management performance through internal collaboration and technological improvements [2][17] Research and Development - **Innovation Initiatives**: CTCM is enhancing its R&D capabilities, establishing collaborative mechanisms, and focusing on the integration of traditional and modern medicine [9][30] - **New Product Development**: The company has launched new products and is conducting clinical tests to enhance market competitiveness [5][26] Future Outlook - **Market Trends**: The company is optimistic about the long-term prospects of the traditional Chinese medicine industry, despite short-term uncertainties due to policy changes [23][31] - **Focus on High-End Markets**: CTCM plans to concentrate on high-end and profitable segments, particularly in the health industry, while seeking to unify market strategies across the nation [28] Additional Considerations - **Management Structure**: CTCM is optimizing its headquarters management structure to better support business segments and enhance decision-making processes [8] - **Executive Compensation**: Executive compensation is linked to market performance, with ongoing evaluations regarding share buyback strategies [18] This summary encapsulates the key points from the conference call, highlighting the financial performance, strategic initiatives, market challenges, and future outlook of China Traditional Chinese Medicine.

Core Viewpoint - China Traditional Chinese Medicine (CTCM) reported a significant decline in net profit by 98.5% for the fiscal year 2024, primarily due to over 100 million yuan in tax payments that severely impacted profitability and highlighted compliance management issues within the company [1][6][7]. Financial Performance - CTCM's revenue for 2024 was 16.51 billion yuan, a decrease of 8.9% year-on-year [4][5]. - The net profit for 2024 was only 20.77 million yuan, marking a drastic drop of 98.5% compared to the previous year [3][5]. - Gross profit fell to approximately 7.86 billion yuan, down 15.3% from 9.27 billion yuan in the previous year, resulting in a gross margin of 47.6%, a decline of 3.6 percentage points [5]. Business Segment Performance - The production and operation of traditional Chinese medicine materials saw a revenue decline of 25.3% [3]. - The Chinese herbal pieces segment experienced a revenue increase of 17.9%, reaching 3.31 billion yuan, although its gross margin was only 23.2% [5]. - The Chinese medicine formula granules segment, once a key revenue driver, saw a 23.5% drop in revenue to 6.97 billion yuan, with a gross margin decrease from 56.9% to 48.3% [5]. Tax Compliance Issues - CTCM acknowledged that the significant drop in net profit was influenced by tax payments totaling approximately 1.53 billion yuan for the years 2017 to 2023, with 1.02 billion yuan already paid [6][7]. - The tax payments are expected to reduce the net profit attributable to shareholders by about 129 million yuan [6]. Market and Strategic Challenges - The company faces intensified market competition and structural changes in demand, particularly due to the implementation of national centralized procurement policies [4][5]. - CTCM's R&D investment for 2024 was 596 million yuan, a decrease of 13.1% from the previous year, which may hinder its competitive position in the market [5]. Stock Performance and Privatization Attempts - CTCM's stock price has been under pressure, with a significant drop following failed privatization attempts by its controlling shareholder, China National Pharmaceutical Group [8][10]. - The stock price fell by 44.5% to 2.12 HKD after the privatization announcement failed, reflecting investor concerns about the company's future [8][10]. Regulatory Environment - The company is under increasing regulatory scrutiny, necessitating a stronger focus on compliance and quality assurance to regain market trust [7][11].

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 16,509.71 million, a decrease of 8.9% compared to RMB 18,121.86 million in 2023[4]. - The net profit for the year was RMB 20.77 million, down 98.5% from RMB 1,396.07 million in the previous year[4]. - The gross profit was RMB 7,856.31 million, a decline of 15.3% from RMB 9,274.49 million, with a gross margin of 47.6%, down 3.6 percentage points from 51.2%[10]. - The company reported a net profit attributable to ordinary shareholders of RMB 54,067,000 for 2024, a significant decrease from RMB 1,285,200,000 in 2023, reflecting a decline of approximately 95.8%[91]. - The group's profit for the year was approximately RMB 20,771,000, a decrease of 98.5% from RMB 1,396,070,000, with a net profit margin of 0.1%, down 7.6 percentage points from 7.7%[103]. Revenue Breakdown - Revenue from traditional Chinese medicine production and operation was RMB 1,386.67 million, a decrease of 25.3%[10]. - Revenue from traditional Chinese medicine decoction pieces increased by 17.9% to RMB 3,314.79 million[10]. - Revenue from traditional Chinese medicine formula granules was RMB 6,972.01 million, down 23.5%[10]. - Revenue from proprietary Chinese medicine was RMB 4,552.96 million, an increase of 14.0%[10]. - Revenue from the traditional Chinese medicine health sector was RMB 283.28 million, a decrease of 19.6%[10]. Market and Industry Insights - The company is optimistic about overcoming short-term performance fluctuations based on insights into the long-term development trends of the traditional Chinese medicine industry[5]. - The comprehensive 200 index for Chinese medicinal materials rose from approximately 2,700 points at the end of 2022 to a peak of over 3,000 points in August 2023, indicating significant volatility and high instability in the market[13]. - The company is focusing on the modernization of traditional Chinese medicine, aligning with national strategies and policies to drive industry growth[17]. Operational Efficiency and Innovation - The company is focusing on digital transformation and innovation to enhance operational efficiency and market competitiveness[6]. - The company has established 165 cooperative production bases across 22 provinces, covering 108 varieties of medicinal materials, with a total area exceeding 470,756 acres[14]. - The company has established 26 direct-operated "Shared Chinese Medicine · Intelligent Distribution Centers" across 20 provinces, improving its operational efficiency[16]. - The company has launched a fresh medicinal slice series to diversify its product offerings and meet the varied demands of the market[16]. Research and Development - The company is focused on research and development of new products and technologies in the Chinese medicine sector[62]. - The company has completed research on 34 out of 51 newly issued national drug standards for traditional Chinese medicine formula granules, accounting for 67%[25]. - The company has developed and launched new traditional Chinese medicine products, including the "Danggui Blood Nourishing Soup Granules," which received approval for market entry[25]. Compliance and Governance - The company has established a comprehensive compliance review system, achieving zero major risk events during the reporting period[31]. - The company has maintained compliance with the corporate governance code throughout the year ending December 31, 2024[120]. - The audit committee consists of five members, including four independent non-executive directors, and has reviewed the audited financial results for the year ending December 31, 2024[123]. Future Outlook and Strategic Planning - The company is expected to benefit from the ongoing reforms in centralized procurement, which aim to enhance transparency and efficiency in the pharmaceutical industry[34]. - Future outlook includes plans for market expansion and potential mergers and acquisitions to enhance growth[62]. - The company aims to enhance user data analytics to improve customer engagement and service delivery[126].

证券时报网讯，摩根士丹利发布报告称，中国中药发布盈利警告，业绩远低于市场预期，因此将其评级 从"与大市同步"下调至"减持"，目标价从2.6港元降至1.7港元，大摩将2024年盈利预测下调80%，并将 2025至2030年的盈利预测下调22%至34%，原因包括价格下调、市场竞争加剧和原材料成本上涨等因素 对销售和利润的影响。 校对：姚远 ...

Financial Performance - The group's revenue for the six months ended June 30, 2024, was approximately RMB 8,385,473,000, a decrease of 9.9% compared to RMB 9,302,957,000 in the same period last year[8]. - Gross profit was approximately RMB 4,061,254,000, down 14.6% from RMB 4,757,976,000 year-on-year, with a gross margin of 48.4%, a decline of 2.7 percentage points from 51.1% in the previous year[8]. - The net profit for the period was approximately RMB 214,143,000, a decrease of 65.3% from RMB 616,960,000 in the same period last year, with a net profit margin of 2.6%[60]. - Basic earnings per share were RMB 0.0419, a decline of 63.5% from RMB 0.1149 in the same period last year, reflecting a significant drop in profit attributable to equity holders[61]. - The company reported a total comprehensive income of RMB 213,958,000, down from RMB 624,763,000, a decrease of 65.75%[85]. - Operating profit decreased significantly to RMB 384,582,000 from RMB 814,046,000, representing a decline of 52.77%[85]. - The group recorded other losses of approximately RMB 64,768,000, compared to losses of RMB 14,004,000 in the same period last year, primarily due to a substantial increase in late fees[52]. - The group’s credit impairment losses were approximately RMB 158,768,000, a significant increase from RMB 47,768,000 in the same period last year, with accounts receivable growing by 6.7%[53]. Revenue Breakdown - The revenue contribution from traditional Chinese medicine formula granules was approximately RMB 3,479,735,000, accounting for 41.5% of total revenue[8]. - The revenue from traditional Chinese medicine (TCM) production and operation was RMB 754,277,000, down 14.3% from RMB 880,585,000, accounting for 9.0% of total revenue[42]. - The revenue from TCM decoction pieces increased by 20.8% to RMB 1,576,914,000 from RMB 1,305,191,000, representing 18.8% of total revenue[44]. - The revenue from TCM formula granules decreased by 29.4% to RMB 3,479,735,000 from RMB 4,930,591,000, with a gross profit margin of 59.1%[45]. - The revenue from TCM proprietary medicines was RMB 2,418,349,000, an increase of 18.9% from RMB 2,034,759,000, with a sales cost of RMB 853,221,000[41]. - The revenue for traditional Chinese medicine health sector was approximately RMB 156,198,000, an increase of 2.9% from RMB 151,831,000 in the same period last year, accounting for 1.9% of total revenue[49]. Strategic Initiatives - The company aims to enhance its competitive advantage across the entire industry chain, focusing on sustainable development and quality management of traditional Chinese medicine resources[11]. - The company has completed mid-term adjustments to its "14th Five-Year" strategic plan, focusing on five major business segments: production and operation of medicinal materials, traditional Chinese medicine pieces, formula granules, proprietary Chinese medicines, and health products[9]. - The company launched a brand strategy for "Chinese Medicinal Materials," promoting key products through major media channels to enhance brand value and influence[10]. - The company is actively adapting to the centralized procurement trend and enhancing its competitive advantages through differentiated product strategies[17]. - The company is focusing on the development of key products and has published 15 new guidelines and consensus documents to support sales growth[19]. Compliance and Quality Management - The company has successfully passed compliance checks for several varieties under the new traditional Chinese medicine GAP standards, leading the nation in the number of compliant varieties[11]. - The company has completed the qualification certification for 47 varieties of fresh-cut medicinal materials, enhancing the quality assurance of traditional Chinese medicine[14]. - The company aims to improve compliance management and risk control mechanisms, ensuring no major risk events occurred during the reporting period[28]. - The company has maintained the highest number of national and provincial standard approvals in the industry, reinforcing its market share[18]. Research and Development - The company has developed 5 new excellent varieties and holds 108 patents related to standardized production techniques for traditional Chinese medicine[11]. - Research and development expenses for the period were RMB 267,925,000, compared to RMB 313,614,000 in the previous year, showing a reduction of 14.58%[85]. - The company established a new CNAS laboratory, bringing the total to 7, and collaborated with Guizhou University to publish research in the journal Nature[22]. Market Trends and Regulatory Environment - The National Medical Insurance Administration issued a notice on January 12, 2024, emphasizing the importance of ensuring supply security for selected products in centralized procurement, requiring provinces to monitor supply and rectify issues[31]. - The National Health Commission's action plan for 2024-2027 aims to shift health work focus from "disease-centered" to "health-centered," promoting traditional Chinese medicine (TCM) as a cultural awareness for health improvement[35]. - The National Administration of Traditional Chinese Medicine's notice on June 6, 2024, emphasized the development of rehabilitation services in TCM hospitals to meet the growing demand for TCM rehabilitation services[35]. Financial Position and Liquidity - As of June 30, 2024, the group's current assets amounted to approximately RMB 20,552,746,000, an increase from RMB 19,799,846,000 as of December 31, 2023[62]. - The group's cash and cash equivalents and bank deposits were approximately RMB 3,771,999,000, up from RMB 3,267,276,000 as of December 31, 2023[62]. - The company had approximately RMB 10,035,352,000 in unused bank loan facilities as of June 30, 2024, indicating a strong liquidity position[65]. - The company’s total liabilities decreased to RMB 9,888,531,000, a rise of 5.97% from RMB 9,332,600,000 as of December 31, 2023[87]. - The company’s total equity attributable to owners increased to RMB 21,371,097,000, compared to RMB 21,160,135,000 as of December 31, 2023, reflecting a growth of 1.00%[87]. Human Resources and Corporate Governance - The company received the "2024 Outstanding Human Resource Management Award" from 51job and was recognized as a favorite employer brand among Chinese university students[24]. - The company is committed to building a comprehensive employer brand and enhancing talent management capabilities[38]. - The company maintained compliance with the corporate governance code throughout the reporting period[79].

Financial Performance - The total revenue for the six months ended June 30, 2024, was RMB 8,385,473, a decrease of 9.9% compared to RMB 9,302,957 for the same period in 2023[2]. - The revenue from traditional Chinese medicine production and operation decreased by 14.3% to RMB 754,277 from RMB 880,585[2]. - The revenue from Chinese medicine decoction pieces increased by 20.8% to RMB 1,576,914 from RMB 1,305,191[2]. - The gross profit for the period was RMB 4,061,254, down 14.6% from RMB 4,757,976 in the previous year[3]. - The net profit attributable to equity holders of the company was RMB 210,979, a decrease of 63.5% compared to RMB 578,742 in the same period last year[2]. - Basic earnings per share decreased to RMB 4.19 from RMB 11.49, reflecting a 63.5% decline[4]. - The company reported a decrease in operating profit to RMB 384,582 from RMB 814,046 in the previous year[3]. - The total profit for the period was RMB 214,143,000, after accounting for unallocated corporate expenses of RMB 3,227,000[13]. - The group reported a net profit of approximately RMB 214,143,000 for the six months ended June 30, 2024, a decrease of 65.3% from RMB 616,960,000 in the previous year, with a net profit margin of 2.6% compared to 6.6% last year[79]. Assets and Liabilities - The total assets as of June 30, 2024, were RMB 27,657,890, slightly down from RMB 27,735,748 as of December 31, 2023[5]. - The total liabilities as of June 30, 2024, were RMB 3,507,314, compared to RMB 3,799,130 as of December 31, 2023[6]. - The total assets of the group amounted to RMB 37,546,421,000, with the Yifang segment holding RMB 16,276,214,000 in assets[14]. - The total liabilities were reported at RMB 13,395,845,000, with the Yifang segment's liabilities at RMB 5,369,781,000[14]. - Current assets as of June 30, 2024, were approximately RMB 20,552,746,000, an increase from RMB 19,799,846,000 as of December 31, 2023, with a current ratio of 2.1[81]. - The group’s bank and other loans amounted to approximately RMB 4,009,484,000 as of June 30, 2024, up from RMB 3,034,020,000 as of December 31, 2023[82]. Revenue Breakdown - For the six months ended June 30, 2024, total revenue reached RMB 8,385,473,000, with a significant contribution from the Yifang segment at RMB 2,964,170,000[13]. - The Tianjiang segment reported a revenue of RMB 2,028,528,000, while the Tongjitang segment generated RMB 1,423,593,000[13]. - Revenue from Chinese herbal formula granules was RMB 3,479,735 thousand, down 29.4% from RMB 4,930,591 thousand year-on-year[19]. - The revenue contribution from traditional Chinese medicine formula granules was approximately RMB 3,479,735,000, accounting for 41.5% of total revenue[36]. - The revenue from TCM patent medicines grew by 18.9% to RMB 2,418,349,000, making up 28.8% of total revenue[68]. - The revenue from TCM health products was RMB 156,198,000, an increase of 2.9% compared to RMB 151,831,000[70]. Expenses and Costs - Research and development expenses for the period were RMB 267,925, down from RMB 313,614 in the previous year[3]. - Financial expenses for the six months ended June 30, 2024, were RMB 84,274 thousand, a decrease from RMB 105,438 thousand in the same period of 2023[24]. - The cost of goods sold for the six months ended June 30, 2024, was RMB 4,324,219,000, a decrease from RMB 4,544,981,000 in the same period of 2023, indicating a reduction of approximately 4.8%[25]. - Sales and distribution costs decreased by 13.6% to approximately RMB 2,752,658,000, down from RMB 3,186,920,000 in the previous year[74]. - Administrative expenses for the six months ended June 30, 2024, were approximately RMB 512,150,000, an increase of 10.2% compared to RMB 464,754,000 for the same period last year[75]. Research and Development - Research and development costs for the six months ended June 30, 2024, amounted to RMB 267,925,000, down from RMB 313,614,000 in the same period of 2023, indicating a decrease of approximately 14.6%[28]. - The company has successfully developed 5 new varieties through standardized production technology, with a total of 108 patents formed[40]. - The company completed research on 19 out of 31 new national standards for traditional Chinese medicine formula granules, accounting for 61%[49]. - The company is focusing on the integration of technology and innovation to strengthen its research and development capabilities[48]. Market and Strategy - The company continues to focus on expanding its market presence through various brands and healthcare solutions[11]. - The company aims to enhance its competitive advantage across the entire industry chain by focusing on sustainable development and resource integration[37]. - The company is actively expanding its market share and enhancing supply capabilities, maintaining the highest number of national and provincial standard approvals[44]. - The company will implement a major brand strategy for "Chinese Medicinal Materials," focusing on brand promotion and exploring international market opportunities[61]. Compliance and Governance - The company has implemented a comprehensive compliance management system, ensuring no major risk events occurred during the reporting period[54]. - The company aims to establish a robust compliance culture and risk identification mechanisms to enhance marketing compliance management and regulatory oversight[61]. - The audit committee reviewed the unaudited consolidated financial performance for the six months ending June 30, 2024, with no disagreements on accounting principles or practices[92]. Sustainability and Social Responsibility - The company is actively promoting green and low-carbon transformation, conducting 78 internal training sessions on energy conservation and environmental protection[53]. - The company was recognized as one of the "Top 100 ESG Listed Companies in China," ranking 25th overall and first among pharmaceutical companies[38].